COMP <GO>
ADPT vs JNJ // FORWARD P/E MULTIPLE
Adaptive Biotechnologies Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: ADPT 4
— JNJ 9
▲ FORWARD P/E MULTIPLE LEADER: JNJ
LAST: $26.64 (-5.43%) • MKT CAP: $4.50B
forward-pe
26.0x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
forward-pe
23.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADPT VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ADPT | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 74.20% | 67.90% | +6.30 | ADPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -12.50% | 25.50% | -38.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.09% | 2.97% | -4.06 | JNJ | /fcf-yield <GO> |
| Operating Margin | -20.60% | 34.70% | -55.30 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -21.50% | 28.50% | -50.00 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 54.80% | 6.00% | +48.80 | ADPT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.32 | 5.59 | +0.73 | ADPT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | ADPT | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.3 | 60.4 | -9.10 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.01 | 1.08 | -0.07 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 26.0x | 23.0x | +3.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.50B | $662.49B | -$658.00B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ADPT REV | JNJ REV | ADPT GROSS % | JNJ GROSS % | ADPT FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $277.0M | $94.19B | 74.2% | 67.9% | -$48.9M | $19.70B |
| FY 2024 | $179.0M | $88.82B | 59.7% | 69.1% | -$98.9M | $19.84B |
| FY 2023 | $170.3M | $85.16B | 44.0% | 44.0% | -$164.0M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADPT // BETA 1.01
JNJ // BETA 1.08